Continued nusinersen treatment for spinal muscular atrophy after earlier study
Part of Brain & nervous system clinical trials.
This trial offers continued treatment with the drug nusinersen (brand name Spinraza) for people with spinal muscular atrophy who completed a specific earlier study of this medicine. It aims to keep providing the treatment while monitoring safety and effects over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have completed the earlier investigational study of nusinersen for spinal muscular atrophy (Study 232SM302).
- Must not have taken any other approved or investigational treatment for spinal muscular atrophy after finishing that study.
- Must be able to attend all study visits and procedures, with support from parents or guardians.
- If female and able to become pregnant (or male of reproductive age), must use effective birth control during the study.
- Must not be pregnant or breastfeeding, and must not plan to become pregnant during the study.
- Must not have a history of severe allergic reaction to nusinersen or its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gives an ongoing treatment called nusinersen (brand name Spinraza) to people who have already been in a previous study for spinal muscular atrophy (SMA). The goal is to keep providing the medicine and to check how safe and effective it is over a longer period.
This trial tests a new gene therapy called GC101 given as a one-time injection into the spinal fluid for people with type 2 spinal muscular atrophy (SMA). It may help improve motor function.
This trial investigates how the drug nusinersen (Spinraza) enters the body when given through a small, flexible tube placed in the lower back (ThecaFlex DRx system). It aims to learn how the drug is processed in adults and children with spinal muscular atrophy, which could help make dosing more convenient.
This study looks at how tired you feel during physical activities while being treated with nusinersen (Spinraza) for spinal muscular atrophy (SMA). The goal is to understand how well the treatment helps with daily energy levels.
This study looks at how Spinraza (nusinersen) taken during or before pregnancy affects people with 5q spinal muscular atrophy (SMA) and the health of their babies. It mainly fits those who were pregnant and received Spinraza around the time of conception or during pregnancy.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
Hear when a new SMA - Spinal Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.